Abstract
We present the SAR study that led us to identification of the first inhibitors of type 7 17β- hydroxysteroid dehydrogenase (17β-HSD). The conversion of E1 into E2 is reduced by nearly 90 % by 17β-(Nalkylformamido)- 4-methyl-4-aza-5α-androstan-3-one compounds bearing a side chain containing 7 to 10 carbon atoms when tested at 0.3 μM.
Keywords: enzyme, hydroxysteroid dehydrogenase, 4-aza-steroids, sar, inhibitors, steroidogenesis
Letters in Drug Design & Discovery
Title: First Inhibitors of the Steroidogenic Enzyme Type 7 17β-Hydroxysteroid Dehydrogenase
Volume: 1 Issue: 3
Author(s): E. Bellavance, V. Luu-The and D. Poirier
Affiliation:
Keywords: enzyme, hydroxysteroid dehydrogenase, 4-aza-steroids, sar, inhibitors, steroidogenesis
Abstract: We present the SAR study that led us to identification of the first inhibitors of type 7 17β- hydroxysteroid dehydrogenase (17β-HSD). The conversion of E1 into E2 is reduced by nearly 90 % by 17β-(Nalkylformamido)- 4-methyl-4-aza-5α-androstan-3-one compounds bearing a side chain containing 7 to 10 carbon atoms when tested at 0.3 μM.
Export Options
About this article
Cite this article as:
Bellavance E., Luu-The V. and Poirier D., First Inhibitors of the Steroidogenic Enzyme Type 7 17β-Hydroxysteroid Dehydrogenase, Letters in Drug Design & Discovery 2004; 1 (3) . https://dx.doi.org/10.2174/1570180043398867
DOI https://dx.doi.org/10.2174/1570180043398867 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Mechanism of Action of Salsolinol in Brain: Implications in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Role of Transforming Growth Factor Beta in Corneal Function, Biology and Pathology
Current Molecular Medicine Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets Nitric Oxide and Cancer Therapy: The Emperor has NO Clothes
Current Pharmaceutical Design Insights into Immunophilin Structure and Function
Current Medicinal Chemistry Listeria monocytogenes as a Vector for Anti-Cancer Therapies
Current Gene Therapy Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics Positron Emission Tomography Imaging of Tumor Hypoxia
Current Medical Imaging Therapeutic Targeting of Chemokines with Monoclonal Antibodies
Current Immunology Reviews (Discontinued) Conotoxins-New Vistas for Peptide Therapeutics
Current Pharmaceutical Design Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy
Current Pharmaceutical Design Therapeutic Potential of High Mobility Group Box-1 in Ischemic Injury and Tissue Regeneration
Current Vascular Pharmacology Advances and Perspectives in Cell-Specific Aptamers
Current Pharmaceutical Design Bioinorganic Chemistry: The Study of the Fate of Platinum-Based Antitumour Drugs
Current Chemical Biology Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Antibodies in Diagnostic Applications
Current Pharmaceutical Biotechnology Molecular Imaging: Translation from Rats to Dogs and Humans
Current Medical Imaging TGF-β Signaling in Gastrointestinal Cancer Stem Cells
Current Cancer Therapy Reviews